CTOs on the Move

Avantor

www.avantorsciences.com

 
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 13,500 strong, our associates are passionate about our ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.avantorsciences.com
  • One Radnor Corporate Center Building One Suite 200. 100 Matsonford Road
    Radnor Township, PA USA 19087
  • Phone: 610.386.1700

Executives

Name Title Contact Details
Michael Wondrasch
 Executive Vice President and Chief Information Officer Profile

Similar Companies

Biosplice Therapeutics

Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing.

Acureon Pharmaceuticals

Acureon Pharmaceuticals is a Berwyn, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Omeros Corporation

Omeros Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Uromedica

Uromedica, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Autolus

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.